Scientific Temporary: Biomarker Testing Technique in Second-Line Remedy
Most important Dialogue Matters:
- Strategic method to biomarker testing when transitioning to second-line remedy
- Significance of liquid biopsy versus tissue biopsy for ESR1 mutation detection
- Position of PIK3CA and different pathway mutations in therapy choice
- Shared decision-making course of for choosing between a number of therapy choices
- Scientific evaluation of endocrine sensitivity length as a therapy predictor
Key Factors for Physicians:
- Liquid biopsy most well-liked for ESR1 mutation detection as a result of subclonal nature (15%-20% higher detection)
- PIK3CA mutations are clonal and detectable within the preliminary tissue biopsy
- Prior CDK4/6 inhibitor response length higher than 12 months signifies endocrine sensitivity
- A number of therapy choices require individualized affected person evaluation
- High quality-of-life issues stability with efficacy outcomes
The dialogue emphasised that endocrine resistance is a posh phenomenon involving a number of pathways, not simply ESR1 mutations, requiring complete biomarker evaluation for optimum therapy choice.
